Scott E. Monroe

No ORCID on file · 5 papers in corpus
article 1997
Dose-related suppression of serum luteinizing hormone in women by a potent new gonadotropin-releasing hormone antagonist (Ganirelix) administered by intranasal spray
·doi:10.1016/s0015-0282(97)80071-4

ObjectiveTo determine if the GnRH antagonist (GnRH-a) Ganirelix (Syntex Research, Palo Alto, CA), administered by intranasal (IN) spray to normal women, is absorbed into the systemic circulation and suppresses LH secretion.DesignA single ce…

article 1995
Effects of a gonadotropin-releasing hormone agonist on the calcium-parathyroid axis and bone turnover in women with endometriosis
American Journal of Obstetrics and Gynecology ·doi:10.1016/0002-9378(95)90348-8

ObjectiveOur purpose was to investigate the effects of nafarelin on bone turnover and mass (bone mineral density, in grams per square centimeter) in women with endometriosis.Study designWe monitored 22 young women with endometriosis during …

book-chapter 1987
Clinical Investigations of the Contraceptive and Therapeutic Potential of Nafarelin
·doi:10.1007/978-94-009-3229-6_17
book-chapter 1987
Treatment of Endometriosis by Nasal Administration of Nafarelin
·doi:10.1007/978-94-009-3229-6_22
article 1985
Treatment of endometriosis with a potent agonist of gonadotropin-releasing hormone (nafarelin)
Fertility and Sterility ·doi:10.1016/s0015-0282(16)48970-3

Administration of superactive agonistic analogs of gonadotropin-releasing hormone (GnRH) has been shown to induce a paradoxic and reversible suppression of gonadotropins, resulting in suppressed gonadal steroid concentrations. Because there…